Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, Wolk sold 13,015 shares of common stock at a weighted average price of $153.89 per share, amounting to approximately $2,002,878.
Prior to this sale, Wolk exercised stock options to acquire the same number of shares at a price of $100.06 per share, just before their expiration. Following these transactions, he holds no direct shares from this exercise but maintains indirect ownership through a spousal lifetime access trust and a 401(k) plan. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with notably low price volatility.
This activity highlights the ongoing financial maneuvers of top executives at major corporations like Johnson & Johnson, which remains a closely watched entity in the pharmaceutical industry.
In other recent news, Johnson & Johnson is planning to sell its stroke care business, Cerenovus, for a valuation of over $1 billion as part of a restructuring plan for its medical technology division. This move follows the company’s ongoing strategy of acquiring medical device makers, with over $30 billion spent in the past three years. In analyst-related news, Guggenheim has maintained a neutral rating on Johnson & Johnson but raised the stock target to $166 following the company’s Q4 2024 results, which reported sales of $22.5 billion and earnings per share of $2.04. Barclays (LON:BARC) also lifted the stock target to $166, noting the company’s solid Q4 performance and consistent growth across its Pharma and MedTech portfolios. However, Bernstein SocGen Group adjusted its outlook, reducing the stock price target to $158. These recent developments reflect the dynamic nature of Johnson & Johnson’s business endeavors and the keen interest of analysts in its financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.